Durban – Aspen, a global multinational specialty pharmaceutical company, was extremely disappointed to learn over the past weekend that specific batches of the Johnson & Johnson COVID-19 vaccine manufactured at our Gqeberha production site and designated for the South African market have to be destroyed due to the Good Manufacturing Practice risk of isolated material… Continue reading Aspen statement on manufacture and supply of COVID-19 vaccines
Aspen is in a closed period from 1st July 2024 until the publication of the FY2024 results on the JSE SENS platform to be released on the 3rd September 2024.
